Compare VTEX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTEX | ABUS |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.3M | 836.0M |
| IPO Year | 2019 | 2008 |
| Metric | VTEX | ABUS |
|---|---|---|
| Price | $4.11 | $4.27 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $5.57 | N/A |
| AVG Volume (30 Days) | 769.7K | ★ 6.3M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.84 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $9.79 | $1,208.75 |
| Revenue Next Year | $7.62 | N/A |
| P/E Ratio | $43.33 | ★ $5.17 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $2.84 | $3.50 |
| 52 Week High | $4.62 | $5.45 |
| Indicator | VTEX | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 39.63 |
| Support Level | $3.51 | $4.12 |
| Resistance Level | $4.20 | $4.57 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 60.71 | 27.33 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.